Aduhelm (aducanumab-avwa) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid solution for intravenous (IV) infusion by a healthcare professional. It’s usually ...

TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody ...

Biogen, one of the world’s oldest independent biotechnology companies, announced new results from a prespecified interim analysis of PRIME, the phase 1b placebo-controlled study of aducanumab (BIIB037 ...

Yesterday, the Food and Drug Administration (FDA) approved aducanumab as a treatment for Alzheimer's. This was history-making, as it was the first medication approved to treat Alzheimer's since 2003.

The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest, with recent ...

The high-profile failure of Biogen’s Alzheimer’s disease drug aducanumab (Aduhelm), punctuated by the company’s decision in January 2024 to discontinue sales, highlights the common struggles faced by ...

Nov 3 (Reuters) - U.S. health experts this week will decide whether to recommend approval for Biogen Inc's (BIIB.O), opens new tab Alzheimer's drug, which could become the first new treatment for the ...

The BMJ is an international peer reviewed medical journal and a fully "online first" publication. Our publishing model–"continuous publication"– means that all articles appear on bmj.com before being ...

The FDA's accelerated approval of aducanumab led to controversy and a congressional investigation, highlighting issues in the approval process. The HHS OIG report found deviations in 3 out of 24 drug ...

Nov 2 (Reuters) - The U.S. Food and Drug Administration, citing conflict of interest, has recused a member of an 11-person advisory committee set to review Biogen Inc's (BIIB.O), opens new tab ...